Depression

Greenbrook TMS Reports First Quarter Operational and Financial Results

Retrieved on: 
Friday, May 13, 2022
General Health, FDA, Mental Health, Medical Devices, Health, Company, U.S. Securities and Exchange Commission, Annual report, Webcast, Patient, Transcranial magnetic stimulation, Depression, FDA, Form 20-F, TMS, Major depressive disorder, Private Securities Litigation Reform Act, Phrase, Risk management

TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.

Key Points: 
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • Greenbrook has provided more than 840,000 TMS treatments to over 24,000 patients struggling with depression.
  • In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.
  • Statements containing forward-looking information are not historical facts but instead represent managements expectations, estimates and projections regarding future events.

neurocare group AG announces TGA approval of Apollo TMS System with product launch at RANZCP Congress in Sydney

Retrieved on: 
Friday, May 13, 2022
AG, Digital, Patient, Depression, TGA, Research, Medicare, TMS, Apollo, Therapeutic Goods Administration, Congress, Transcranial magnetic stimulation, Technology, DTP, Mental health, Royal Australian and New Zealand College of Psychiatrists, Government, Australian Government, GLOBE, Pharmaceutical industry

neurocare will be launching the Apollo TMS system at the upcoming Royal Australian & New Zealand College of Psychiatry (RANZCP) 2022 Congress, held in Sydney from May 15-19, 2022.

Key Points: 
  • neurocare will be launching the Apollo TMS system at the upcoming Royal Australian & New Zealand College of Psychiatry (RANZCP) 2022 Congress, held in Sydney from May 15-19, 2022.
  • Alongside the Medicare rebates, neurocare CEO Thomas Mechtersheimer believes the Apollo TMS System will be a game changer in the treatment of depression: "TGA approval of our Apollo TMS system, which already has regulatory approval in Europe and the United States, marks an important step forward in Australian psychiatry.
  • The annual RANZCP Congress provides a unique opportunity to connect with Australian psychiatrists interested in treatment innovations and updates in their field.
  • Earlier this year, neurocare's two-part training for clinicians looking to integrate TMS was accredited by RANZCP and is currently the only RANZCP endorsed TMS training courses in the country.

ABVC BioPharma Engages the FreeMind Group to Support Grant Funding

Retrieved on: 
Friday, May 13, 2022
NSF, Company, Stanford University, U.S. Securities and Exchange Commission, Patient, DOD, NASDAQ, Depression, NIH, San Francisco, FDA, FreeMind, CNS, University of California, San Francisco, Forward-looking statement, Cedars-Sinai Medical Center, University, Technology, Risk, Pancreatic cancer, Ophthalmology, PERT, SEC, Cancer, Security (finance), CA, BARDA, GLOBE, Pharmaceutical industry

FreeMind has a knowledgeable and experienced team of project managers with the ability to help ABVC identify the most suitable grant opportunities and assist in preparing and submitting the applications.

Key Points: 
  • FreeMind has a knowledgeable and experienced team of project managers with the ability to help ABVC identify the most suitable grant opportunities and assist in preparing and submitting the applications.
  • Over the last 10 years, their work has helped their clients to receive over $1.7 billion in non-dilutive funding.
  • We are hopeful that this collaboration will allow us to fund more of our promising clinical trials from non-dilutive capital sources, said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma.
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.

Is Your Dog Overweight? It May Be at Risk of Developing This Debilitating Disease

Retrieved on: 
Friday, May 13, 2022
Joint, Inflammation, Pain, Exercise, Personality, Depression, Overweight, Arthritis, Feedback, FDA, PETS, Time, VCA, Diet, Chronic pain, Dog, Cartilage, Hunting

VENTURA, Calif., May 13, 2022 /PRNewswire/ -- According to the Veterinary Centers of America (VCA), 50% of all dogs are overweight or obese. This should be of immediate concern to all dog owners as pets that carry extra weight are far more likely to develop arthritis and other serious joint issues, such as hip dysplasia.

Key Points: 
  • Pet Wellness Direct advises on how to protect your pet from pain and mobility issues.
  • VENTURA, Calif., May 13, 2022 /PRNewswire/ -- According to the Veterinary Centers of America (VCA), 50% of all dogs are overweight or obese.
  • It can cause painful wear and tear on dog joint cartilage and joint fluid, which can impact a dog's mobility and energy, and even its personality.
  • Because when a dog is dealing with chronic pain, it can become depressed and despondent and even aggressive."

Free Parenting Program Helps Orange County Children Navigate Anxiety and Fear

Retrieved on: 
Thursday, May 12, 2022
Social Media, Primary, Secondary, Education, Communications, Other Consumer, Preschool, Women, Parenting, Children, Men, Family, Science, Consumer, Other Science, Research, Online, HCA, Anxiety, Ageing, Research, Journal, Family, Â, Mental health, Fear, OC, Multimedia, Recovery, The Journal of Pediatrics, Parent, Caregiver, Depression, Time, Student, Program, Pet recovery service, Attention, Sadness, Prevalence, CDC, Friends, Health policy, Grammatical mood, Residential care, Medicine, Tutoring, Lynch, Pediatrics

The Fear-Less Triple P online program provides the timely mental health support we need today, and we are thrilled to make it available for free to every OC parent and caregiver.

Key Points: 
  • The Fear-Less Triple P online program provides the timely mental health support we need today, and we are thrilled to make it available for free to every OC parent and caregiver.
  • The campaign directs families to a free online course at www.triplep.online supported by clinical evidence showing the best ways to help children break free from fear and anxiety.
  • We believe that OC parents who take advantage of this free program will feel and see their own skills improve at raising confident, capable children children who are able to energetically explore their world without being held back by fear.
  • What Im learning from the Fear-Less program is how to better start conversations with my children about those stressesand thats made a big difference for us.

Court Order Authorizes GENECIS Clinic Physicians to Resume Gender-Affirming Care for Transgender Kids for 14 Days

Retrieved on: 
Thursday, May 12, 2022
Patient, Physician, Suicide, Depression, Medical Center, Topical steroid withdrawal, Children's Medical Center Dallas, Program, Legal case, Gender dysphoria, Marketing, Medicine, University of Texas Southwestern Medical Center, Child

DALLAS, May 12, 2022 /PRNewswire/ -- A court in Dallas County has issued a temporary restraining order that authorizes physicians at Children's Medical Center to resume providing gender-affirming care, including hormone treatment and puberty blockers, for transgender youth who were previously treated under the banner of the GENECIS clinic.

Key Points: 
  • "But UT Southwestern and others put up roadblocks to keep us from finding out the truth about who closed down GENECIS.
  • We'll do this another way and in the process, we'll take care of kids who need this treatment."
  • According to Children's and UT Southwestern's own marketing, the GENECIS clinic was the first and largest program in the southwest providing care to transgender youth.
  • However, amid criticism of such therapy from conservative politicians, UT Southwestern and Children's shut down the GENECIS clinic in the fall of 2021.

DEPRESSION AND BIPOLAR SUPPORT ALLIANCE TO HONOR THREE OUTSTANDING ACHIEVERS IN MENTAL HEALTH RESEARCH AT 2022 KLERMAN AWARDS CEREMONY MAY 22

Retrieved on: 
Thursday, May 12, 2022
Drinking, Knowledge, Anxiety, Global Health, Gerald, Lists of diseases, Alcohol, National, Collaborative RESearch Team to study psychosocial issues in Bipolar Disorder (CREST.BD), Suicidal ideation, Patient, National Institute, Mental health, Collaboration, Gerald Klerman, American Society for Pharmacology and Experimental Therapeutics, Quality of life, Therapy, Clinical trial, DBSA, McGovern Medical School, National academy, Mortality, Bipolar disorder, University, Depression, Autism, Research, Psychosis, Psychotherapy, Bipolar, Genetics, TRD, National Institute of Mental Health, Disability, CDT, Harvard Medical School, Panic, NIMH, Coronavirus Scientific Advisory Board (Turkey), Depression and Bipolar Support Alliance (Greater Houston), Diagnosis, Schizophrenia, SAB, GLOBE, Pharmaceutical industry, Medicine

Chicago, IL, May 12, 2022 (GLOBE NEWSWIRE) -- CHICAGO (May 12, 2022) The Depression and Bipolar Support Alliance (DBSA), and its Scientific Advisory Board (SAB) will honor three clinicians for their contributions to mental health research at the 2022 Klerman Awards ceremony.

Key Points: 
  • Chicago, IL, May 12, 2022 (GLOBE NEWSWIRE) -- CHICAGO (May 12, 2022) The Depression and Bipolar Support Alliance (DBSA), and its Scientific Advisory Board (SAB) will honor three clinicians for their contributions to mental health research at the 2022 Klerman Awards ceremony.
  • Gerald L. Klerman was an educator, researcher, clinician, author, and administrator who specialized in depression, schizophrenia, panic, and other anxiety disorders.
  • Their relentless pursuit of progress in mental health research ensures a brighter future of improved diagnosis and treatments for those living with depression and bipolar disorder.
  • This year, the Klerman Awards ceremony celebrates these outstanding achievers in mental health research:
    Dr. Zarate is Chief, Experimental Therapeutics and Pathophysiology Branch, at the National Institute of Mental Health (NIMH).

Global Sleeping Aids Market (2022 to 2030) - Share, Size, Trends, Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 12, 2022
Health, Pharmaceutical, Insomnia, Sleep disorder, Pain, List of Hindawi academic journals, Forecasting, Population, Narcolepsy, R, OSA, Traction, Sleep apnea, National Sleep Foundation, Patient, Investment, Revenue, USD, Lists of diseases, Depression, Sleep, Industry, Awareness, Obstructive sleep apnea, Tobacco, CAGR, Prevalence, Pharmaceutical industry

The "Sleeping Aids Market Share, Size, Trends, Industry Analysis Report, By Product; By Sleep Disorders; By Region; Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sleeping Aids Market Share, Size, Trends, Industry Analysis Report, By Product; By Sleep Disorders; By Region; Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global sleeping aids market size is expected to reach USD 118.31 billion by 2030 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The publisher has segmented the sleeping aids market report on the basis of product, sleep disorder, and region:
    Sleeping Aids, Product Outlook (Revenue - USD Billion, 2018 - 2030)

FORMER SENIOR DIRECTOR SUES TARGET CORPORATION FOR DISCRIMINATION, RETALIATION AND DEFAMATION

Retrieved on: 
Monday, May 16, 2022
Senior, Death, Social Security Government Pension Offset, Biophysical environment, Bias, Leadership, Corporate responsibility, Disability, Weakness, Depression, Complaint, Culture, Riot, Anxiety, Defamation, Corporation, LLC, Male, Target Corporation, Social, Company, ESG, Insurance, Management, Target

MINNEAPOLIS, May 12, 2022 /PRNewswire/ -- Molly Haney, a former Senior Director terminated in September 2021 after almost fourteen years of exceptional performance, has sued Target Corporation in Hennepin County alleging disability and gender discrimination, retaliation, and defamation.

Key Points: 
  • MINNEAPOLIS, May 12, 2022 /PRNewswire/ -- Molly Haney, a former Senior Director terminated in September 2021 after almost fourteen years of exceptional performance, has sued Target Corporation in Hennepin County alleging disability and gender discrimination, retaliation, and defamation.
  • SCHAEFER HALLEEN SUES TARGET CORPORATION FOR FORMER SENIOR DIRECTOR ALLEGING DISCRIMINATION, RETALIATION AND DEFAMATION
    Ms. Haney worked in Target's "Corporate Responsibility" function reporting to Senior Vice President Amanda Nusz.
  • The Complaint specifically identifies Ms. Haney as one of three Senior Directors who were direct reports of SVP Nusz in 2021.
  • All three have left Target and accused SVP Nusz of discrimination and retaliation.

Harvard MedTech Appoints Anita Breedlove Vice President of Market Partnerships

Retrieved on: 
Thursday, May 12, 2022
Mental Health, Health, Technology, Other Health, Physical Therapy, Software, Senior, Risk, Anita, Pain, Harvard University, Patient satisfaction, Patient, Science, Pain management, Trauma, Solution, Virtual reality, Pharmacy, Metabolic pathway, Depression, Sleep, Algorithm, Health Care Service Corporation, Industry, PTSD, Partnership, PBM, Anxiety, Conduent, Business administration, Breedlove, Northwood University, Medical imaging, Medicine, Woman

Anita Breedlove has been appointed Vice President of Market Partnerships at Harvard MedTech , a breakthrough digital health company pioneering Vx Therapy that comprehensively integrates virtual reality with behavioral health for the treatment of the effects of trauma, including pain, without drugs or surgery.

Key Points: 
  • Anita Breedlove has been appointed Vice President of Market Partnerships at Harvard MedTech , a breakthrough digital health company pioneering Vx Therapy that comprehensively integrates virtual reality with behavioral health for the treatment of the effects of trauma, including pain, without drugs or surgery.
  • Anita is an accomplished sales and client management executive in workers compensation who brings additional breadth and depth to our market partnership initiatives, said Mark Moore, Senior Vice President, Market Partnerships.
  • Her knowledge of the workers compensation industry, coupled with her consultative skills, will prove invaluable to the clients and injured workers served by Harvard MedTech.
  • Anitas focus will be on Harvard MedTechs relationships with workers compensation carriers, third party administrators, self-insured employers, managed care organizations, pharmacy benefit management firms (PBMs) and alternative networks.